2023

  1. Matsubara, D., Yoshimoto, T., Akolekar, N., Totsuka, T., Amano, Y., Kihara, A., Miura, T., Isagawa, Y., Sakuma, Y., Ishikawa, S., et al. (2023). Genetic and phenotypic determinants of morphologies in 3D cultures and xenografts of lung tumor cell lines. Cancer Sci https://doi.org/10.1111/cas.15702.
  2. Dai, T., Adachi, J., Dai, Y., Nakano, N., Yamato, M., Kikuchi, S., Usui, S., Minami, Y., Tomonaga, T., Noguchi, M., et al. (2023). In-depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation. Cancer Med-us. 10.1002/cam4.5766.

2022

  1. H Kawai; R Matsuoka; T Ito; D Matsubara. Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC? Frontiers Biosci Landmark Ed 27, 108 (2022) https://doi.org/10.31083/j.fbl2703108.
  2. Shiba-Ishii, A. et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer 1–13 (2022) doi:10.1038/s43018-022-00399-6.
  3. Matsuoka, R., Kawai, H., Ito, T. & Matsubara, D. Determining Whether YAP1 and POU2F3 Are Antineuroendocrine Factors. J Thorac Oncol 17, 1070–1073 (2022).

~2021

  1. Matsubara, Daisuke; Yoshimoto, Taichiro; Soda, Manabu; Amano, Yusuke; Kihara, Atsushi; Funaki, Toko; Ito, Takeshi; Sakuma, Yuji; Shibano, Tomoki; Endo, Shunsuke; Hagiwara, Koichi; Ishikawa, Shumpei; Fukayama, Masashi; Murakami, Yoshinori; Mano, Hiroyuki; Niki, ToshiroReciprocal expression of TFF-1 (trefoil factor-1) and TTF-1 (thyroid transcription factor-1) in lung adenocarcinomas. Canser Sci, 2020 in press (IF:4.966)
  2. Takeshi Ito, Atsuko Nakamura, Ichidai Tanaka, Yumi Tsuboi, Teppei Morikawa, Jun Nakajima, Daiya Takai, Masashi Fukayama, Yoshitaka Sekido, Toshiro Niki, Daisuke Matsubara*, and Yoshinori Murakami. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 & LATS2 in lung tumors predicts good prognosis. Canser Sci, 2019;110:2284-2295. doi: 10.1111/cas.14040. (corresponding author, co-last author) Cancer Science2019年7月号のハイライト論文(IF:4.966)
  3. Matsubara D, Soda M, Yoshimoto T, Amano Y, Sakuma Y, Yamato A, Ueno T, Kojima S, Shibano T, Hosono Y, Kawazu M, Yamashita Y, Endo S, Hagiwara K, Fukayama M, Takahashi T, Mano H, Niki T. Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-TRU-type lung adenocarcinomas. Cancer Sci, 2017 Jul 5. doi: 10.1111/cas.13313. (IF:4.966)
  4. Ito T, Matsubara D*, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y. Loss of YAP1 Defines Neuroendocrine Differentiation of Lung Tumors. Cancer Sci, 2016;107:1527-1538. doi: 10.1111/cas.13013. (corresponding author) (IF:4.966)
  5. Matsubara D, Kishaba Y, Yoshimoto T, Sakuma Y, Sakatani T, Tamura T, Endo S, Sugiyama Y, Murakami Y, Niki T. Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer. Pathol Int. 64: 560-8, 2014. (IF:2.110)
  6. Ibrahim R, Matsubara D*, Osman Y, Morikawa T, Goto A, Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J, Fukayama M, Niki T, Murakami Y. Expression of PRMT5 in lung adenocarcinoma and its significance in epithelial-mesenchymal transition. Human Pathol. 45: 1397-1405, 2014 (corresponding author) (IF:2.740)
  7. Matsubara D, Kishaba Y, Ishikawa S, Sakatani T, Oguni S, Tamura T, Hoshino H, Sugiyama Y, Endo S, Murakami Y, Aburatani H, Fukayama M, Niki T. Lung Cancer with Loss of BRG1/BRM, shows Epithelial Mesenchymal Transition Phenotype and Distinct Histologic and Genetic Features. Cancer Sci. 2013;104(2):266-73. (IF:4.966)
  8. Matsubara D, Kanai Y, Ishikawa S,Ohara S, Yoshimoto T, Sakatani T, Oguni S,Tamura T, Kataoka H, Endo S, Murakami Y, Aburatani H, Fukayama M and Niki T. Identification of CCDC6-RET Fusion in a Human Lung Adenocarcinoma Cell Line, LC-2/ad.J Thorac Oncol. 2012;7(12):1872-6. (IF:13.357)
  9. Matsubara D, Niki T. Epidermal Growth Factor Receptor Mutation and Chemosensitivity. J Thorac Oncol. 2012;7(4):771-772. (IF:13.357)
  10. Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol. 2010;177(5):2191-2204. (IF:3.762)
  11. Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol. 2010;5:1317-24.Journal of thoracic oncoly 2010年9月号のハイライト論文(IF:13.357)
  12. Matsubara D, Morikawa T, Goto A, Nakajima J, Fukayama M, Niki T. Subepithelial myofibroblast in lung adenocarcinoma: a histologic indicator of excellent prognosis. Mod Pathol. 2009;22:776-85. (IF:6.365)
  13. Matsubara D, Niki T, Ishikawa S, Goto A, Ohara E, Yokomizo T, Heizmann CW, Aburatani H, Moriyama S, Moriyama H, Nishimura Y, Funata N, Fukayama M Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathologic significance, relationship to p53, and identification of their target genes. Cancer Sci. 2005;96:844-57. (IF:4.966)

Image

筑波大学　医学医療系　診断病理学研究室
〒305-8575　茨城県つくば市天王台1-1-1
☎︎ 029-853-3150　FAX 029-853-3150
受付時間：9:00 - 17:00

筑波大学附属病院　病理部・病理診断科
〒305-8576　茨城県つくば市天久保2-1-1
☎︎ 029-853-3865　FAX 029-853-3752
受付時間：8:30 - 17:00

Copyright© 2021 筑波大学　医学医療系　診断病理学 All Rights Reserved.

トップページ